Stellar Biotechnologies shares shot up more than 60 percent May 31 after the company’s shareholders approved a deal with Canadian therapeutics firm Edesa Biotech that could see it wind down its Port Hueneme operations. The deal leaves current Stellar shareholders with a 10 percent interest in Edesa, while Edesa investors retain the other 90 percent,…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
